BIO-TECHNE Corp vs Twilio Inc — how do they compare? BIO-TECHNE Corp trades at $72.46 (market cap $11.37B), while Twilio Inc trades at $276.51 (market cap $41.93B). The key difference: Twilio Inc is far larger — about 3.7× BIO-TECHNE Corp's market cap, and BIO-TECHNE Corp pays a 0.44% dividend while Twilio Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold BIO-TECHNE Corp for 63 Days and Twilio Inc for 56 Days on average.
| TECH | TWLO | |
|---|---|---|
Market Cap | $11.37B | $41.93B |
Volume | 3,153,511 | 3,480,421 |
Sector | Health | Technology |
52-Week High | $72.61 | $301.27 |
52-Week Low | $43.31 | $106.23 |
Typical Hold Time | 63 Days | 56 Days |
Enterprise Value | $11.40B | $40.34B |
Dividend Yield | 0.44% | — |
Signals from Pluang's Aura AI — not financial advice
TECH trades at $72.53, near its 52-week high of $72.70, with a bullish technical signal and strong institutional interest. Recent earnings show mixed results, beating in Q2 2026 but missing in Q1. The company maintains solid profitability with a 65.77% gross margin, though net income declined to $73.40M in 2025. Shareholders approved an acquisition by Merck KGaA at $73.00 per share, a key near-term catalyst.
Outlook is positive due to the pending acquisition, but risks include execution challenges and valuation concerns with a high P/E of 62.53. Analyst consensus is divided with 46% buy ratings, suggesting cautious optimism. The stock offers limited upside to the acquisition price, making it suitable for event-driven investors.
Twilio (TWLO) trades at $273.00, down 2.64% on the day, with a bullish technical signal from moving averages and neutral oscillators. The company has beaten EPS estimates for three consecutive quarters, with Q3 2026 results pending. Revenue growth accelerated to $5.07 billion in 2025, turning net income positive at $33.83 million after prior losses. Recent inclusion in the S&P 500 index highlights institutional recognition, while analyst consensus remains strongly bullish with 76.9% buy ratings.
Outlook is positive given earnings momentum and S&P 500 inclusion, but high valuation multiples (P/E 37.71, EV/EBITDA 80.78) pose risks if growth slows. Competitive pressures in customer engagement software and potential volatility from AI-driven sentiment shifts require monitoring. The stock trades above the consensus price target of $254.65, suggesting near-term consolidation may precede further gains if execution continues.
Trailing returns across standard periods
What Pluang investors did over the last 30 days
No sentiment data available yet.
Latest headlines on both assets
Based in Minnesota, Bio-Techne is a life sciences manufacturer supplying consumables and instruments for the pharma, biotech, academic, and diagnostic markets. The company reports in two segments, protein sciences (75% of revenue), and diagnostics and genomics (25%). The protein-focused segment makes equipment and associated consumables for protein characterization and analysis and sells antibodies for research and clinical purposes. In diagnostics, Bio-Techne provides controls and calibrators for diagnostic manufacturers and has a portfolio of diagnostic oncology assays. The United States accounts for about 55% of revenue, and the firm also has operations in EMEA (20% of sales), the U.K. (5%), and APAC (15%), with the rest of the world accounting for the remaining 5%.
Read more on TECH →Twilio Inc. is a cloud-based communication platform-as-a-service company offering communication building blocks that allow for a fully customized customer engagement experience spanning voice, video, chat, and SMS messaging. It does this through various application programming interfaces, or APIs, and prebuilt solution applications aimed at improving customer engagement. The company leverages its Super Network, a global network of carrier relationships, to facilitate high-speed, cost-effective communication.
Read more on TWLO →